Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MighTeaFlow, Xylitol · 1 trial · 3 indications
Change in salivary flow in Xerostomic patients using Green tea lozenges
| Arm | Type | Description |
|---|---|---|
| MighTeaFlow | ACTIVE_COMPARATOR | 4-6 times daily lozenge containing green tea, jaborandi extracts, and 500 mg xylitol for 8 weeks |
| Xylitol | ACTIVE_COMPARATOR | 4-6 times daily lozenge containing jaborandi extract, and 500 mg xylitol for 8 weeks |
| Name | Type | Description |
|---|---|---|
| MighTeaFlow | DIETARY_SUPPLEMENT | 4-6 times daily |
| Xylitol | DIETARY_SUPPLEMENT | 4-6 times daily |
Inclusion Criteria: 1. A complaint of dry mouth as assessed by a response of 30mm or greater on a Dry Mouth Visual Analog Scale (VAS) 2. Clinical Diagnosis of primary or secondary Sjogren's syndrome. 3. Over the age of 18. 4. Taking less than three drugs associated with causing xerostomia or saliva...
MighTeaFlow, Xylitol is an investigational drug being studied for the management of xerostomia, commonly known as dry mouth. It is also being evaluated in patients with Sjogren syndrome, a condition that can cause dry mouth. The drug is currently in Phase 1 clinical development.
MighTeaFlow, Xylitol is being developed by GSK plc, a global biopharmaceutical company. GSK plc is publicly traded under the ticker symbol GSK on the stock market.
MighTeaFlow, Xylitol is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials to evaluate its safety and efficacy.
MighTeaFlow, Xylitol has been studied in one completed clinical trial, identified as NCT01647737, titled "Green Tea Lozenges for the Management of Dry Mouth." This Phase 1 trial enrolled 60 participants with xerostomia, Sjogren syndrome, or dry mouth, and was conducted in the United States.
MighTeaFlow, Xylitol is a drug product that contains xylitol as a component, but it is not the same as plain xylitol. The drug is being developed by GSK plc for the management of dry mouth, and it is currently in Phase 1 clinical trials.